Results 71 to 80 of about 41,733 (183)

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

Cancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda, Kazuo Hasegawa, Takayuki Takahama, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Masashi Yoshida, Miyuki Sakai, Sachiko Watanabe, Kazuhiko Nakagawa   +9 more
wiley   +1 more source

Spatiotemporal dynamics of β‐arrestin‐mediated Src activation in 5‐HT7 receptor signaling pathway

The FEBS Journal, EarlyView.
GPCRs induce distinct cellular responses via G protein‐ or β‐arrestin‐mediated signaling pathways. This study revealed that β‐arrestin‐biased 5‐HT7R ligand induces slow, sustained Src activation, contrasting with transient G protein‐mediated activation.
Hyunbin Kim, Yong Woo Lee, Huimin Lee, Eunseo Park, Jieon Lee, Hae Nim Lee, Kyeong‐Man Kim, Hyunah Choo, Jihye Seong   +8 more
wiley   +1 more source

Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines

BRAFV600 Mutationen sind ein negativer Prognosefaktor beim kolorektalen Karzinom, welches typischerweise resistent gegen BRAF-Inhibitoren ist. Etliche Resistenzmechanismen sind HSP90-abhängig, sodass eine Kombination von BRAF- und HSP90-Inhibition einen vielversprechenden Ansatz darstellt. Allerdings ist die Datenlage bislang ungenügend.
openaire   +2 more sources

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Investigation of Oncogenic Gene Mutation and Associated Protein Expression in Ameloblastic Carcinoma

Oral Diseases, EarlyView.
ABSTRACT Objective This study aimed to investigate gene mutations in ameloblastic carcinoma (AC) including BRAF, KRAS, and PIK3CA, along with associated protein expressions of BRAF V600E, p‐ERK1/2, and p‐mTOR, which represent activation of MAPK/ERK and PI3K/mTOR pathways, respectively.
Puangwan Lapthanasupkul, Jintana Pankam, Siribang‐on Piboonniyom Khovidhunkit, Prapapun Seneetuntigul, Nakarin Kitkumthorn   +4 more
wiley   +1 more source

Variant‐Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs

International Journal of Cancer, Volume 159, Issue 7, Page 1715-1734, 1 October 2026.
Mutual exclusivity and co‐occurrence of oncogenic mutations reflect functional antagonism or dependence and may inform therapeutic strategies. However, most studies overlook variant‐level patterns. In this comprehensive, cross‐cohort analysis of BRAF, KRAS, and EGFR mutation subtypes, the most significant mutual exclusivity pairs overlapped with ...
Freya Vaeyens, Jan‐Patrick Hetzel, Khaldoon Abdullah, Carolien Eggermont, Catharina Olsen, Marco Mernberger, Ken Maes, Jelle Vlaeminck, Rainer Claus, Dries Vanisterbecq, Frederik Hes, Martin Pichler, Philippe Giron, Oleg Timofeev, Maxim Noeparast   +14 more
wiley   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

BRAF V600E Mutation in Odontogenic Keratocyst: A Systematic Review and Meta-Analysis

Pesquisa Brasileira em Odontopediatria e Clínica Integrada
Objective: To assess the frequency of the BRAF V600E mutation in odontogenic keratocyst, correlating the methods of evaluation and detection of the mutated protein.
Jéssica da Silva Cunha, Lucas Nascimento Ribeiro, Allan Vinícius Martins-de-Barros, Raisa Jordana Geraldine Severino-Lazo, Raíssa Soares dos Anjos, Renata de Albuquerque Cavalcanti Almeida, Mohammed N. Islam, Marianne de Vasconcelos Carvalho   +7 more
doaj  

Association of SIGLEC9 Expression with Cytokine Expression, Tumor Grading, KRAS, NRAS, BRAF, PIK3CA, AKT Gene Mutations, and MSI Status in Colorectal Cancer

Current Issues in Molecular Biology
SIGLEC9 (sialic acid-binding Ig-like lectin 9) is a molecule thought to have a significant influence on the immune properties of the colorectal cancer (CRC) tumor microenvironment (TME).
Błażej Ochman, Anna Kot, Sylwia Mielcarska, Agnieszka Kula, Miriam Dawidowicz, Dominika Koszewska, Dorota Hudy, Monika Szrot, Jerzy Piecuch, Dariusz Waniczek, Zenon Czuba, Elżbieta Świętochowska   +11 more
doaj   +1 more source

Histiocytosis development and clinical variation through the lens of genomics

The Journal of Pathology, Volume 270, Issue 1, Page 23-39, September 2026.
Abstract Histiocytic neoplasms are rare haematologic diseases characterised by clonal expansions of cells with a monocyte, macrophage or dendritic cell phenotype. Their clinical manifestations are diverse, ranging from indolent lesions to aggressive systemic disease.
Paul G Kemps, Astrid GS van Halteren, Tom van Wezel, Pancras CW Hogendoorn   +3 more
wiley   +1 more source